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ABSTRACT: Tens of thousands of genetic association stud-
ies investigating the influence of common polymorphisms
on disease susceptibility have been published to date.
These include ∼1,000 genome-wide association studies
(GWAS). This vast amount of data in the field of com-
plex genetics is becoming increasingly difficult to follow
and interpret. It can be expected that the situation will
become even more complex with the advent of association
projects using “next-generation” technologies. One of the
aims of the HumanVariome Project is to concatenate such
data in meaningful ways, for example, within the con-
text of publicly available field synopses. Here, we present
various examples of online genetic association databases
developed by our group for neuropsychiatric disorders.
One integral part of this model is the systematic inclusion
of data from large-scale genotyping projects, for example,
GWAS, while respecting the privacy of data contributors.
We believe that our database approach may serve as a vi-
able model that can be readily applied to other fields and
ultimately improve our understanding of the genetic forces
driving common human conditions.
HumMutat 33:1366–1372, 2012. C© 2012Wiley Periodicals, Inc.
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Introduction
Most, if not all, common diseases are caused by an interplay of
genetic and environmental factors. In many diseases, there is also
often a small subset of subjects that inherit the respective condition
in a Mendelian fashion (e.g., <5–10% of patients suffering from
Alzheimer’s (AD) or Parkinson’s disease (PD) [Lill and Bertram,
2011]. However, the majority of disease cases are of a multifactorial
and polygenic nature and are thus often labeled as being “genet-
ically complex.” Because the identification and elucidation of the
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underlying genetic architecture have oftentimes promising implica-
tions for disease prevention and early treatment [e.g., see Collins,
2010], the efforts and money spent in this field of genetic epidemi-
ology have been enormous. Literally, tens of thousands of genetic
association studies, that is, studies that investigate the influence
of usually common genetic variants on disease susceptibility, have
been published to date. For instance, the number of such studies
published for some of the most common neuropsychiatric diseases
alone, including AD, PD, schizophrenia, amyotrophic lateral sclero-
sis (ALS), and multiple sclerosis (MS) amounts to almost 5,000 at
the time of writing (Fig. 1). This vast amount of information is be-
coming increasingly difficult to follow, evaluate, let alone interpret.
To this end, the vision of the Human Variome Project (HVP) is “to
develop a global collaboration with the aim of building systems and
strategies for the collection, storage, interpretation and sharing of
human genetic variation and its implications for disease” [Haworth
et al., 2011]. Along these lines, the HVP has emphasized the need
for disease-specific genetic association databases that would system-
atically identify and collect the relevant data, quantitatively assess
the impact of genetic variants on complex disorders, and make the
results available in high-quality, user-friendly databases [Haworth
et al., 2011; Cotton et al., 2007]. Independently from the HVP, our
group has already developed and continues to maintain a number
of such genetic association databases for neuropsychiatric diseases
[Allen et al., 2008; Bertram et al., 2007; Lill et al., 2011, 2012] such
as AD, PD, ALS, MS, and schizophrenia. The approach behind these
database projects represents the focus of this article as it may serve
as one model to achieve the abovementioned goals outlined by the
HVP. Furthermore, challenges and potential problems related with
the databases’ construction and maintenance will be discussed.
State-of-the-Art Genetic Research in Complex
Diseases
The field of genetic epidemiology in complex diseases has expe-
rienced a tremendous shift in recent years owing to the feasibility of
generating and analyzing high-throughput genotyping data, such as
those typically produced in the context of genome-wide association
studies (GWAS). This “GWAS era” has followed more than three
decades of candidate-gene-based association studies. This approach
typically only investigated a limited number of variants across single
genes or sets of genes based on functional considerations. Notwith-
standing its simplicity and low scale, this approach successfully let
to the identification of some risk genes for a number of diseases,
usually the individually most important risk loci, that is, those exert-
ing the largest risk effects. These major risk loci were subsequently
largely confirmed in recent GWAS [Siontis et al., 2010]. For the
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Figure 1. Simplified overview of literature search, data extraction, and analysis strategies applied to the database projects described in this
article. “Coremeta-analyses” refer tometa-analyses displaying individual-study results, that is, derived fromGWAS and/or candidate gene studies.
This flowchart has been modified after Lill and Bertram (2010).
last few years, GWAS, which test several hundred thousand poly-
morphisms in the same experiment, have nominated hundreds of
additional disease risk loci across complex diseases. In contrast to
the confirmed candidate gene findings, however, these typically ex-
ert only small to modest risk effects [Hindorff et al., 2009]. Current
candidate-gene association studies are now typically focused on val-
idating the most promising GWAS results in independent datasets
or on performing secondary GWAS analyses (e.g., pathway-based
analyses). These candidate-gene studies continue to be important to
distinguish false-positive from genuine signals, to refine GWAS as-
sociation signals by fine-mapping approaches, as well as to possibly
identify additional variants not meeting the stringent significance
thresholds in primary GWAS analyses. Furthermore, smaller-scale
studies often provide a framework to investigate the newly pro-
posed risk variants in distinct populations and ethnicities for which
no GWAS data have been generated, and thus allow to assess the uni-
versality of genetic disease risk profiles [e.g., Sharma et al., 2012].
Thus, despite the undeniable success of the GWAS approach in
expanding our knowledge and understanding about the genetic ar-
chitecture of common diseases, assessing the cumulative evidence
of association continues to be essential, but—for reasons outlined
below—is becoming more and more difficult to achieve. One main
limiting factor is that many GWAS datasets are not shared with
outside investigators. But even if full access to the GWAS data has
been granted, the computational challenges, that is, processing, an-
alyzing, and correctly interpreting these data, remains one major
bottleneck when assessing the evidence for genetic risk factors of
interest. It can be expected that this situation will become several
orders of magnitude more complex with the expected advent of
genetic association projects using next-generation sequencing tech-
nologies, for example, via whole-exome or whole-genome sequenc-
ing [Green and Guyer, 2011]. To this end, it has been recognized that
“generally applicable tools are needed in the form of robust, well-
engineered software that meets the distinct needs of genomic and
non-genomic scientists. Adequate computational infrastructure is
also needed, including sufficient storage and processing capacity
to accommodate and analyze large, complex data sets (including
metadata) deposited in stable and accessible repositories, and to
provide consolidated views of many data types, all within a frame-
work that addresses privacy concerns” [Green and Guyer, 2011].
This calls for a “next-generation” of genetic association databases
with an appropriate infrastructure to incorporate large-scale asso-
ciation data, that is, GWAS and next-generation sequencing data.
In the following paragraphs, we will present the genetic database
approach of our group. A particular focus will be laid on recent
novel developments that now allow to systematically include some
of the above described large-scale data, that is, those originating
from GWAS. Our systematic approach to data collection, analysis
and annotation as well as database design may serve as a model for
genetic association databases of other diseases to meet the needs and
standards of researchers in the twenty-first century.
Database Design and Structure
General Approach
The databases developed by our group [for more details on these
databases, see Allen et al., 2008; Bertram et al., 2007; Chatzinasiou
et al., 2011; Lill et al., 2011, 2012] aim to serve as an exhaustive
and regularly updated resource of genetic association studies for the
respective diseases. They do not only allow a qualitative overview
of genetic association studies in each field, but also provide quan-
titative assessments of the cumulative evidence for association of
individual polymorphisms by calculating and providing up-to-date
meta-analyses on all eligible polymorphisms.
Applicable association studies are identified by continuous
PubMed searches and by systematically screening the references
of relevant publications (e.g., primary association papers, but also
reviews and published meta-analyses). A publication is included in
one of our databases if it assesses the association of a polymor-
phism (defined as DNA sequence variants with ≥1% frequency in
the general population) with risk for disease, and if it has been pub-
lished in a peer-reviewed English language journal. Demographic
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details of included studies (such as ethnicity of the investigated
datasets, number of subjects, sex and age distribution, and diagnos-
tic criteria) are extracted from each publication, and summarized
in the respective databases. Furthermore, and most importantly,
genetic association data (e.g., genotype summary data, allele fre-
quencies or odds ratios [ORs], and confidence intervals) for each
reported polymorphism are extracted from the publication. Meta-
analyses are performed on bi-allelic polymorphisms (e.g., SNPs,
indels) investigated in a case-control setting and available in at least
four independent datasets. Meta-analysis results are displayed for
all ethnicities combined, as well as after stratification for different
ethnic background, provided sufficient data are available. Family-
based studies without available subject-level data are excluded from
meta-analyses due to often insufficient and inconsistent reporting of
results (however, datasets including unrelated case-control subjects
enriched for familial cases are not excluded). Data on mitochondrial
DNA variants are excluded because of the multicopy nature of the
mitochondrial genome, and the high frequency of somatic mutation
events that vary substantially across tissues. Also, data of obviously
“poor” quality are excluded if apparent discrepancies could not be
resolved after contacting the study authors (see below). For more
details on background and methods, see Lill et al. (2012).
Inclusion of GWAS Datasets
As pointed out above, the data derived from GWAS have become a
substantial resource of unbiased association data and their inclusion
is essential for the validity and success of any genetic association
database. To this end, the genetic databases developed by our team
[Allen et al., 2008; Bertram et al., 2007; Chatzinasiou et al., 2011; Lill
et al., 2011, 2012] list all published GWAS in the respective diseases
fields in a dedicated overview section, which provides demographic
characteristics of the included samples and highlights those loci
that have been “featured” as potential disease loci in the respective
publications.
Furthermore, all GWAS data provided in the respective publi-
cations themselves, that is, usually data on the top signals of that
study (i.e., “featured genes”) or those postulated by previous stud-
ies, can be included in the databases even if the full GWAS data
or results are not shared by the primary authors. However, while
these results provide the most interesting findings of that partic-
ular study, this approach alone could lead to selective reporting
bias. Therefore, in addition and, most importantly, access to all
existing GWAS datasets is sought (if publicly available usually by
application via dbGaP [http://www.ncbi.nlm.nih.gov/gap], or else
by directly contacting study authors). In case of the availability of
subject-level data, they are cleaned using common quality control
steps (i.e., removing duplicate or related samples within and across
GWAS datasets, removing individuals and SNPs with insufficient
genotyping efficiency, removing SNPs violating Hardy–Weinberg
equilibrium), and data are subject to genotype imputation and as-
sociation analysis [Marchini et al., 2007]. This includes adjustment
for population structure, and, if available, age and sex (for more
details on GWAS dataset preparation and analysis, see Lill et al.,
2012). Alternatively, we also include GWAS summary statistics gen-
erated and provided by the authors, that is, ORs and standard errors
(SEs). These can easily be integrated into meta-analyses already ex-
isting for any given polymorphism on the respective databases. This
procedure does not require subject-level data and may therefore
alleviate the process of (and the concerns that come with) sharing
of individual-level GWAS data. After preparation and formatting of
the GWAS datasets, meta-analyses are performed or updated across
eligible SNPs, that is, based on all available data from GWAS as well
as pre- and post-GWAS “candidate-gene” approaches. This process
also allows to add a substantial amount of unbiased GWAS data to
many meta-analysis results that otherwise would be derived from
candidate-gene data alone. In addition to being showcased on our
databases themselves, all meta-analysis results (i.e., P values and di-
rections of effect) are also displayed on a customized UCSC genome
browser track [Kent et al., 2010].
Privacy Protection Policies
It has now been demonstrated by several groups that the prob-
ability of an individual being the member of a specific cohort, for
which large-scale genotyping data are available, can be estimated
under some conditions even from some types of summary statistics
[e.g., Homer et al., 2008; Jacobs et al., 2009; Sankararaman et al.,
2009]. As a consequence, this has led to more restrictive data sharing
policies for GWAS and other large-scale data, for example, regulated
data access policies via dbGaP. Obviously, these restrictions and is-
sues need to be considered in the framework of genetic association
databases to ensure the maximally possible degree of privacy pro-
tection of any individual who has contributed their data to GWAS.
However, it needs to be emphasized that to resolve potential cohort
membership requires several premises that are not applicable in the
context of our database approach. First, membership probabilities
can be estimated if summary allele frequencies or genotype counts
are provided [Craig et al., 2011]. This is one of the reasons why new
versions of the databases developed and maintained by our group do
not display summary genotype data or allele frequencies for large-
scale data but only rounded ORs and SEs (adjusted for population
substructure and age and sex if available). Estimating membership
probabilities from such data becomes more difficult with increas-
ing numbers of included subjects [Craig et al., 2011]. Second, the
number of SNPs, for which genotype summary counts or allele fre-
quencies are needed to resolve cohort membership, is rather large
to allow an accurate prediction. Furthermore, the precision of the
probability estimate decreases with an increasing number of indi-
viduals genotyped in the cohort. For instance, Craig et al. could show
that sharing genotype summary data for∼1,000 SNPs from cohorts
of >500 individuals yields very low positive predictive values [Craig
et al., 2011], that is, membership cannot be reliably estimated. Most
GWAS performed to date, in fact, have included more than 500
combined cases and controls [Hindorff et al., 2009]. Earlier GWAS,
possibly with numbers falling below this threshold, have often been
superseded by later efforts from the same groups then involving
extended datasets, that is, typically >500 individuals. While privacy
protection concerns related to information publicly displayed across
our databases thus lack any rationale, we took the following addi-
tional measures to ensure maximal protection of privacy of GWAS
participants. (1) As outlined above, genotype summary data or al-
lele counts or frequencies for large-scale association studies are not
being displayed. Instead, we only showcase rounded and adjusted
ORs and SEs per dataset. (2) Study-level results (i.e., rounded ORs
and SEs) of GWAS and other large-scale association studies are dis-
played only for a subset of SNPs, that is, up to a maximum of 10,000
SNPs. These SNPs include the most relevant SNPs investigated in the
respective diseases, that is, the “top results” of GWAS and GWAS-
derived meta-analyses as well as SNPs investigated in candidate-gene
approaches of the pre- and post-GWAS era. (3) Meta-analysis results
of SNPs that are not part of the “top 10,000 SNPs” (i.e., results from
GWAS-only meta-analyses showing no compelling evidence for as-
sociation) are being displayed without detailing study-level ORs or
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Figure 2. Screenshot of the PDGene database showing a Manhattan plot of all available meta-analysis results. This screenshot shows the
“GWAS overview” page of the PDGene database (http://www.pdgene.org/largescalemeta.asp) presenting P values from >7 million meta-analyses
results including fully available, imputed GWAS datasets (back and gray dots), and meta-analysis results based on a combination of “pre- and
post-GWAS candidate-gene studies and fully or partially available GWAS data where applicable (green dots). For more details, see Lill et al. (2012).
SEs. However, the database allows to investigate the combined evi-
dence for association for all meta-analyzed polymorphisms (based
on P values and direction of effect, see also Fig. 2).
Linking Different Disease-Related Databases
Our databases are cross-linked, for example, on the gene and poly-
morphism level, which allows a direct comparison of association
results across different neuropsychiatric diseases. This functionality
will be extended in future releases of our database software.
Database Code
The newly designed database code will be made available upon
request to interested researchers from other disease fields on a col-
laborative basis.
Limitations, Practical Difficulties, and Ways
to Deal with Them
While the above-described approach appears relatively straight-
forward, its practical implementation typically turns out to be much
more complex and laborious than outlined. In extreme cases, this
sometimes even requires revision of the applied database cura-
tion strategies. Here, we will discuss what we consider the major
challenges related to what determines (in our opinion) the accep-
tance and success of genetic association databases, or any scientific
database: completeness, correctness, and timeliness of data display.
Completeness
As we have shown previously, completeness of the identified liter-
ature in the context of genetic association studies can successfully
be achieved by searches of NCBI’s PubMed database and, within
individual publications, cross-checking for additional references.
Screening of additional literature databases has not led to the iden-
tification of additional articles meeting our inclusion criteria [Allen
et al., 2008; Lill et al., 2012]. As literature screening is a process still
requiring a large amount of human interaction, and since the accu-
racy of this process is essential for all subsequent database curation
and analysis steps, employing a person with pre-existing knowledge
and experience in the field is obviously advantageous. However,
although the manual literature screenings seem to rarely miss eligi-
ble articles based on our experience, this process has a rather low
specificity. For instance, while building and regularly updating the
PDGene database, a total of ∼27,000 citations had been screened
until March, 2011 [Lill et al., 2012]. The major burden of PubMed
screening relates to the “updating” process. Only about 8,300 cita-
tions were screened during database construction, and 19,200 sub-
sequently during database maintenance. However, altogether only
3% of all screened PubMed citations fulfilled our inclusion criteria.
This process can be streamlined by applying artificial intelligence,
for example, self-learning data mining methods. Usage of a recently
described algorithm that aimed at this goal substantially reduced
the burden of manual literature searches [Wallace et al., 2012]: this
particular algorithm can be trained on a “discovery dataset” of el-
igible articles and subsequently yields 100% sensitivity and ≥90%
specificity for identification of PubMed citations when updating
literature searches.
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Furthermore, fulfilling the completeness criterion depends on the
extent to which the relevant data are available. Despite the existence
of established guidelines on the reporting of genetic association
studies, that is, the STREGA guidelines [Little et al., 2009], miss-
ing data in publications remain an important issue that can come
in different forms and shapes. The most common problems are
undisclosed names and/or genetic association results (genotypes,
allele counts, or summary statistics [ORs and CIs]) of polymor-
phisms that have been investigated. It is rather frequent in certain
disease fields that even in smaller-scale studies no genotype sum-
mary data or allele frequencies are provided; in these situations,
inclusion of allelic or additive ORs and CIs—if provided in the
respective publication—can reduce the amount of missing data.
Importantly, the database’s data extraction protocol should specify
in advance which covariates are accepted for inclusion of published
ORs/CIs/SEs. Unfortunately, it is relatively common in genetic as-
sociation studies to provide ORs and P values, but not necessarily
CIs or SEs, which makes inclusion of these data more difficult. One
potential solution to this problem is afforded by simulations of geno-
type data based on reference allele frequencies as implemented in
our novel database code. Furthermore, a major and often underes-
timated and underappreciated problem is the missing specification
of direction of effect, for example, the situation where genotype
summary data/allele frequencies are named without specifying the
minor and major allele, or providing ORs without specifying risk
or reference alleles. A similar situation occurs for ambiguous allele
names, that is, A/T and C/G—here strand information would be
necessary to define allele assignments, although this only affects a
small subset of studies thus far included in our databases [Lill et al.,
2010]. In both situations, it is often possible to resolve missing al-
lele designations or to deduce strand information by comparing
allele frequencies with ethnicity-specific reference panels such as
HapMap or 1000 Genomes. This is now achieved automatically in
a new version of our database code soon to be launched publicly.
However, this can only be done allele if minor/major frequencies
are not too similar; we have defined this as allele frequencies <0.4
in the study dataset and/or reference panel. If missing data still pre-
cludes inclusion of datasets in the respective meta-analyses, authors
must be contacted and asked to provide the relevant missing infor-
mation. Our team does this by usually contacting the first and/or
last authors twice via e-mail. Regardless of all attempts to resolve
the missing data problem, up to 8% of small-scale association data
remain unavailable for inclusion [Allen et al., 2008; Lill et al., 2012].
Unavailability of individual-level or study-level data from large-
scale association datasets, most commonly GWAS, obviously aggra-
vate the “missing data” problem quite considerably. This typically
relates to individual-level data if they are not available via public
platforms such as dbGaP. However, our experience shows that it
is often feasible to at least obtain subsets of the missing data in a
collaborative effort with the investigators of the primary GWAS.
Possible scenarios include the sharing of summary statistics, that is,
ORs, and SEs, but not subject-level data, for the full dataset or only
a subset of SNPs (e.g., ∼1,000 to 10,000 SNPs, which includes the
top results of that dataset as well as those SNPs already entered in
the respective database)
Correctness
To avoid curational errors during the screening of the literature,
the inclusion of studies, and the extraction of relevant data it has
proven advantageous in our experience that the most important
processes and data entries in the database are double-checked by a
second team member. This double-checking is crucial for the data
extraction processes where study designs can be misinterpreted or
random errors can occur and possibly lead to erroneous meta-
analysis results. In case of persisting disagreement, consensus is
reached by consulting a third colleague, typically the supervisor.
Even our general inclusion criterion of requiring publication in
a peer-reviewed journal does not exclude studies of minor quality.
Most common concerns are inadequate study design (e.g., biased
selection of study subjects), and errors in genotyping/sequencing
protocols or discrepancies in terms of allele names or frequen-
cies when compared with public references. Naturally, the more
experienced the database curators are, the better can such er-
rors be identified, with subsequent correction or exclusion of data
from meta-analysis. In addition, a few consistency checks can also
be performed algorithmically by the database code, for example,
comparing allele assignments and frequencies to public databases
such as dbSNP. As we include common polymorphisms in our
databases, we report the respective official identifiers (NCBI’s “rs-
numbers,” http://www.ncbi.nlm.nih.gov/sites/SNP) where applica-
ble and available, including hyperlinks to the “dbSNP” database
which extensively annotates all variants using the nomenclature
system espoused by the Human Genome Variation Society (HGVS,
www.hgvs.org/mutnomen). Some studies publish polymorphism
data without the respective official identifiers. In these instances,
additional and sometimes extensive curational efforts are needed
to assess whether the assignment to an official identifier is pos-
sible based on sequence information provided in the respective
publications and comparison to public databases (e.g., Ensembl,
http://www.ensembl.org/index.html). If not applicable, we report
the polymorphism names as published in the respective publications
to ensure consistency with the primary publications. In addition to
these study-specific polymorphism names, we annotate variants
based on HGVS nomenclature whenever this is possible based on
the sequence context information provided in the primary publi-
cations. Another important concern relates to the lack of correctly
identifying overlaps across datasets. This can lead to inflated and po-
tentially biased meta-analysis results. Criteria applied by our group
that result in an in-depth assessment for potential overlaps are:
similarities in demographic details (e.g., overlapping recruitment
regions) and shared coauthors. In case that overlap is suspected but
not declared by the authors of the respective publication(s), authors
are contacted for clarification. Although this procedure can identify
systematic sample overlap, it does not exclude random overlap (e.g.,
a subject recruited for two independent studies). However, this is a
rather rare occurrence. Further, we have recently shown that even
an unidentified sample overlap of up to 10% does not appreciably
change the meta-analysis results [Lill et al., 2012].
Timeliness of Data Display
In contrast to “conventional” reviews or meta-analyses, which
can provide an excellent snapshot and/or in depth analysis of the
genetic knowledge at the time of publication but are often quickly
outdated, genetic association data included in a database format
can provide up-to-date resources for the respective fields if they are
continuously updated. However, this obviously depends a contin-
uous funding of the underlying curational efforts. Our experience
shows that funding for the initial development and launch of such
databases is still relatively easy, whereas funding for continuous
database updates is sometimes more difficult to obtain. When seek-
ing long-term funding, database curators should keep in mind that
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this not only requires support for the curatorial team, but should
also cover sufficient funds for updates to the database code.
Other Limitations
In addition to the points listed above, other limitations exist that
are inherent to the methodological approach and often cannot be
resolved. For instance, the approach developed and adopted by our
group aims to assess the cumulative evidence of main effects, and as
such are usually based on study-level summary data. This often pre-
cludes the completion of “refined” analyses such as applying geno-
typing quality control filters, inclusion of potential confounders,
analyses of gene–gene and gene–environment interactions, and—if
GWAS data are available only on a summary level—de novo imputa-
tion of genotypes (e.g., upon publication of a new reference panel),
investigation of copy-number variants, or calculation of individual
risk scores. Another limitation is inherent to the concept of probing
for genetic association between a polymorphism and certain trait,
that is, that the genetic variants included need to fulfill a certain
minimum frequency threshold to lead to meaningful results. Across
our database projects, this amounts to only including polymor-
phisms with a minor allele frequency of at least 1% in the general
population. Thus, dominant mutations or rare alleles with frequen-
cies below 1% are excluded. However, disease-causing mutations
are sometimes covered by other online resources dedicated to just
this purpose. In the neurogenetics field, excellent examples of such
“mutation databases” include the “AD&FTD Mutation Databases”
[Cruts and Van Broeckhoven, 1998; Gijselinck et al., 2008], the
“PD Mutation Database” [Nuytemans et al., 2010], and “ALSoD,” a
database for mutations relevant in ALS [Wroe et al., 2008]. To learn
more about these databases, please consult the respective websites
and accompanying contributions in this special issue of Human
Mutation.
The Shape of Things to Come in Complex
Diseases
As outlined above, genetic association databases have not lost
their significance in the “GWAS era.” Due to the complex nature of
GWAS, the contrary appears to be the case, provided that these types
of studies can be included. Within the next years, additional GWAS
datasets will be generated for many diseases, for instance, in popu-
lations and ethnic groups that have thus far been largely neglected.
These will need to be included in ongoing meta-analyses of ge-
netic association data. Furthermore, projects using next-generation
sequencing technologies to generate genetic association data have
already started, and can be expected to pick up momentum over the
next decade, eventually fully replacing microarray-based GWAS of
current times. Obviously, data generated by these powerful studies
will need to be included into existing databases. To this end, Green
and Guyer [Green and Guyer, 2011] already stated that “large data
catalogues [. . .] are community resources. This calls for policies that
maximize rapid data release (harmonized internationally), while re-
specting the interests of the researchers generating the data and the
human participants involved in that research.” As outlined in this
article, the database structure developed by our group already allows
the inclusion of such data (from GWAS) without compromising the
privacy of genotyped individuals or the interest of the researchers
performing such studies. Eventually, however, the success of genetic
association databases will depend predominantly on (1) the avail-
ability/sharing of such large scale datasets, and (2) on the availability
of continuous funding.
Conclusion
Online databases represent an excellent resource to comprehen-
sively concatenate and present data from a diverse range of scientific
fields, including results from genetic association studies. For the lat-
ter, systematic inclusion of large-scale datasets such as GWAS and
next-generation sequencing studies are becoming increasingly cru-
cial for the quality, usefulness, and acceptance of such databases.
However, systematic inclusion of such studies also represents one of
the most difficult steps due to a number of reasons, including com-
putational and/or algorithmic challenges, as well as restrictions in
data sharing policies. For nearly a decade, our group has been active
in the development and curation of genetic association databases.
New developments in the database code now extend this process to
the systematic inclusion of large-scale genotyping data, if these are
shared. Thus, our approach may serve as a viable model of deal-
ing with the increasing amount of genetic data being generated by
thousands of laboratories worldwide to improve our understanding
of the genetic forces driving common human diseases.
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